Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer.
One hundred and forty-nine patients with early cancer of the ovary who were suitable for postoperative radiotherapy were treated in a random study in which whole abdominal irradiation with additional treatment to the pelvis was compared to chemotherapy with Melphalan. The number of patients without evidence of disease at 2 yr seems to show that the results of treatment are similar. When the Berkson-Gage method of projection is used, however, the survival rate in stage I is apparently improved with irradiation; there is only a minor difference in the results of the two methods in stage II, and survival rates are improved for patients with stage III disease who were treated with chemotherapy. The complications of treatment in this study were quite different. Melphalan was well tolerated, and only one patient had serious bone marrow depression as a result of this treatment. All had prompt recovery of blood counts to normal after completing the prescribed chemotherapy. Seven patients treated by radiotherapy developed a small bowel injury which required surgery. Six of these were treated with irradiation to the pelvis followed by strip irradiation to the entire abdomen. This treatment plan probably gives excessive doses of irradiation to the pelvis and has been discontinued. This type of complication is much less frequent with the other sequence of treatment--strip irradiation to the whole abdomen and subsequent treatment to the pelvis. The cost to the patient of the two treatment programs varied considerably. Patients who received irradiation had the added expense of living in Houston for the duration of treatment. Patients treated with chemotherapy were often seen a 2- or 3-mo intervals and had their chemotherapy supervised by their personal physician.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011182:Postoperative Care; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D008558:Melphalan